@article{ac638f84d48341a881c0a83e932b4a42,
title = "Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology",
abstract = "Primary systemic light chain amyloidosis (SLCA) is characterized by production of light chains that get converted to amyloid fibrils with an affinity for visceral organs and causing organ dysfunction. The therapy for SLCA is directed to recovering the function of the affected organs by targeting the abnormal plasma cell clone and slowing deposition of amyloid fibrils. The NCCN Guidelines for SLCA provide recommendations for workup, diagnosis, and treatment of primary as well as previously treated SLCA.",
author = "Kumar, {Shaji K.} and Callander, {Natalie S.} and Kehinde Adekola and Anderson, {Larry D.} and Muhamed Baljevic and Erica Campagnaro and Castillo, {Jorge J.} and Caitlin Costello and Christopher D{\textquoteright}Angelo and Srinivas Devarakonda and Noura Elsedawy and Alfred Garfall and Kelly Godby and Jens Hillengass and Leona Holmberg and Myo Htut and Huff, {Carol Ann} and Malin Hultcrantz and Yubin Kang and Sarah Larson and Lee, {Hans C.} and Michaela Liedtke and Thomas Martin and James Omel and Aaron Rosenberg and Douglas Sborov and Jason Valent and Ryan Berardi and Rashmi Kumar",
note = "Publisher Copyright: {\textcopyright} 2023 National Comprehensive Cancer Network{\textregistered} (NCCN{\textregistered}). All rights reserved.",
year = "2023",
month = jan,
doi = "10.6004/jnccn.2023.0001",
language = "English (US)",
volume = "21",
pages = "67--81",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "1",
}